ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
Launch of Broker Offer to raise a maximum of £500,000
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce that the project subject to the Evaluation
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health today provides an update on progress towards the completion of the